<li>acebutolol<p>acebutolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>aldesleukin<p>aldesleukin increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>alfuzosin<p>alfuzosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>amifostine<p>amifostine increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amphetamine<p>amphetamine decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>asenapine<p>asenapine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>atenolol<p>atenolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>avanafil<p>avanafil increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>axitinib<p>amlodipine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>bisoprolol<p>bisoprolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>boceprevir<p>boceprevir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>calcium acetate<p>calcium acetate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium chloride<p>calcium chloride decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium citrate<p>calcium citrate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium gluconate<p>calcium gluconate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carbidopa<p>carbidopa increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.</p></li><li>carvedilol<p>carvedilol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>celiprolol<p>celiprolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased effect of calcium channel blockers may lead to hypotension, edema, decreased HR, and acute kidney injury due to reduced renal blood flow</p></li><li>clevidipine<p>amlodipine and clevidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>cobicistat<p>cobicistat will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.</p></li><li>crofelemer<p>crofelemer increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>amlodipine increases levels of cyclosporine by unspecified interaction mechanism. Modify Therapy/Monitor Closely. A prospective study in renal transplant recipients averaged a 40% increase in cyclosporine trough levels.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and amlodipine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diltiazem<p>amlodipine and diltiazem both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>doxazosin<p>doxazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>esmolol<p>esmolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>felodipine<p>amlodipine and felodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>flibanserin<p>amlodipine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>iloperidone<p>iloperidone increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>isradipine<p>amlodipine and isradipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>labetalol<p>labetalol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>lacidipine<p>amlodipine and lacidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>lercanidipine<p>amlodipine and lercanidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>lesinurad<p>lesinurad decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levodopa<p>levodopa increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>lomitapide<p>amlodipine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>lurasidone<p>lurasidone increases effects of amlodipine by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maraviroc<p>maraviroc, amlodipine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>mefloquine<p>mefloquine increases levels of amlodipine by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.</p></li><li>metoprolol<p>metoprolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>mitotane<p>mitotane decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>moxisylyte<p>moxisylyte and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nebivolol<p>nebivolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nicardipine<p>amlodipine and nicardipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nifedipine<p>amlodipine and nifedipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nisoldipine<p>amlodipine and nisoldipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, amlodipine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>nitroglycerin sublingual<p>amlodipine, nitroglycerin sublingual.
Either increases toxicity of the other by additive vasodilation. Modify Therapy/Monitor Closely. Marked orthostatic hypotension reported with concomitant use.</p></li><li>nitroprusside sodium<p>amlodipine increases effects of nitroprusside sodium by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider dose reduction for amlodipine.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease dose of calcium channel blocker; dose of amlodipine should be decreased by at least 50%; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. if such events occur, consider further dose reduction of  calcium channel blocker or switching to alternative to calcium channel blocker <span><br><br></span>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of amlodipine by  altering metabolism. Modify Therapy/Monitor Closely. Decrease dose of calcium channel blocker; dose of amlodipine should be decreased by at least 50%; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. if such events occur, consider further dose reduction of  calcium channel blocker or switching to alternative to calcium channel blocker </p></li><li>penbutolol<p>penbutolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>phenoxybenzamine<p>phenoxybenzamine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>phentolamine<p>phentolamine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>prazosin<p>prazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>propranolol<p>propranolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>saquinavir<p>saquinavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>silodosin<p>silodosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>simeprevir<p>simeprevir increases levels of amlodipine by decreasing metabolism. Modify Therapy/Monitor Closely. May result in increased plasma concentrations of calcium channel blockers due to intestinal CYP3A4 and/or P-gp inhibition by simeprevir.</p></li><li>sotalol<p>sotalol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tacrolimus<p>amlodipine will increase the level or effect of tacrolimus by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Adjust dose when appropriate.</p></li><li>tadalafil<p>tadalafil increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telaprevir<p>telaprevir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Exposure to amlodipine was increased when co-administered with telaprevir. Caution should be used and dose reduction for amlodipine should be considered. Clinical monitoring is recommended.</p></li><li>terazosin<p>terazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>timolol<p>timolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>tipranavir<p>tipranavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous, amlodipine.
Either increases effects of the other by Other (see comment). Use Caution/Monitor. 
Comment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness.</p></li><li>verapamil<p>amlodipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole increases levels of amlodipine by decreasing metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>zotepine<p>zotepine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li>